Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small…
Biotechnology
US, South San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 0.95 | -56.60 | -57.14 | |
| Graham Fair Price | -0.28 | 10.77 | 10.81 | |
| PEG | 144.70 | -3.23 | 1.32 | |
| Price/Book | 6.12 | 4.43 | 4.18 | |
| Price/Cash Flow | 32.05 | -55.72 | -82.00 | |
| Prices/Earnings | 4.58 | -18.29 | -19.17 | |
| Price/Sales | inf | 0.00 | 1422.24 | |
| Price/FCF | 32.05 | -55.72 | -82.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 0.79 | |
| Operating Margin | inf | 0.00 | -23.46 | |
| ROA | -11.25 | -0.06 | -0.05 | |
| ROE | -0.05 | -0.06 | -11.22 | |
| ROIC | -0.07 | -0.07 | -9.63 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.06 | 0.42 | -85.54 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.19 | -0.03 | 86.63 | |
| EPS QOQ | 0.15 | -0.06 | -61.01 | |
| FCF QOQ | -0.08 | -0.48 | -509.39 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.01 | 0.01 | -0.94 | |
| Quick Ratio | 18.89 | 18.50 | -2.04 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 9.76 | 9.23 | -5.44 | |
| Cash | 10.07 | 9.37 | -6.94 | |
| Capex | -0.02 | < 0.005 | 86.09 | |
| Free Cash Flow | -0.50 | -0.73 | -47.68 | |
| Revenue | 0.03 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad